BFEC
NVO

Benjamin F. Edwards & Company’s Novo Nordisk NVO Stock Holding History

Benjamin F. Edwards & Company’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$3.71M Buy
25,979
+57
+0.2% +$7.55K 0.07% 274
2024
Q1 		$3.33M Buy
25,922
+2,095
+9% +$249K 0.06% 272
2023
Q4 		$2.46M Buy
23,827
+19,517
+453% +$1.93M 0.05% 305
2023
Q3 		$392K Sell
4,310
-222
-5% -$19.6K 0.02% 581
2023
Q2 		$367K Buy
4,532
+14
+0.3% +$1.14K 0.01% 580
2023
Q1 		$359K Sell
4,518
-158
-3% -$11.2K 0.02% 561
2022
Q4 		$316K Buy
4,676
+296
+7% +$17.4K 0.01% 589
2022
Q3 		$218K Buy
4,380
+2,812
+179% +$151K 0.01% 649
2022
Q2 		$87K Hold
1,568
– – ﹤0.01% 904
2022
Q1 		$87K Sell
1,568
-158
-9% -$8.11K ﹤0.01% 897
2021
Q4 		$97K Buy
1,726
+10
+0.6% +$542 ﹤0.01% 886
2021
Q3 		$82K Sell
1,716
-20
-1% -$967 ﹤0.01% 904
2021
Q2 		$73K Sell
1,736
-28
-2% -$1.08K ﹤0.01% 935
2021
Q1 		$59K Sell
1,764
-212
-11% -$7.55K ﹤0.01% 960
2020
Q4 		$69K Sell
1,976
-1,000
-34% -$34.6K ﹤0.01% 883
2020
Q3 		$103K Sell
2,976
-394
-12% -$13.1K 0.01% 732
2020
Q2 		$110K Buy
3,370
+388
+13% +$12.4K 0.01% 713
2020
Q1 		$90K Sell
2,982
-18
-0.6% -$536 0.01% 718
2019
Q4 		$87K Buy
3,000
+1,058
+54% +$29.3K 0.01% 825
2019
Q3 		$50K Sell
1,942
-100
-5% -$2.53K ﹤0.01% 933
2019
Q2 		$52K Sell
2,042
-200
-9% -$4.94K ﹤0.01% 892
2019
Q1 		$59K Sell
2,242
-200
-8% -$4.92K 0.01% 834
2018
Q4 		$56K Sell
2,442
-1,400
-36% -$31.1K 0.01% 801
2018
Q3 		$91K Sell
3,842
-100
-3% -$2.44K 0.01% 701
2018
Q2 		$91K Sell
3,942
-100
-2% -$2.38K 0.01% 699
2018
Q1 		$100K Sell
4,042
-30
-0.7% -$788 0.01% 675
2017
Q4 		$109K Sell
4,072
-488
-11% -$12.4K 0.01% 624
2017
Q3 		$110K Sell
4,560
-600
-12% -$13.6K 0.01% 583
2017
Q2 		$111K Sell
5,160
-498
-9% -$10K 0.01% 547
2017
Q1 		$97K Sell
5,658
-1,460
-21% -$25.4K 0.01% 555
2016
Q4 		$128K Buy
7,118
+2,800
+65% +$50.8K 0.02% 455
2016
Q3 		$90K Buy
4,318
+400
+10% +$9.92K 0.02% 453
2016
Q2 		$105K Sell
3,918
-1,232
-24% -$33.8K 0.02% 414
2016
Q1 		$140K Buy
5,150
+146
+3% +$3.91K 0.03% 344
2015
Q4 		$145K Sell
5,004
-86
-2% -$2.38K 0.03% 356
2015
Q3 		$138K Buy
5,090
+1,072
+27% +$30.4K 0.03% 360
2015
Q2 		$110K Buy
4,018
+518
+15% +$14.6K 0.02% 440
2015
Q1 		$93K Hold
3,500
– – 0.02% 454
2014
Q4 		$74K Sell
3,500
-100
-3% -$2.23K 0.02% 443
2014
Q3 		$86K Buy
3,600
+1,000
+38% +$23K 0.02% 423
2014
Q2 		$60K Buy
2,600
+1,400
+117% +$30.9K 0.02% 453
2014
Q1 		$27K Buy
+1,200
New +$25.6K 0.01% 530

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Benjamin F. Edwards & Company's NVO Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its Novo Nordisk (NVO) stake by 0.22% in Q2 2024, buying an estimated $7.55K and bringing the position to 25,979 shares worth $3.71M. The position accounts for 0.07% of the portfolio, ranked #274.

Benjamin F. Edwards & Company first reported a position in NVO in Q1 2014 and has held it in 42 quarters since. 1,863 funds tracked by Wall St. Rank hold NVO as of Q2 2024.

  • Benjamin F. Edwards & Company held 25,979 shares of Novo Nordisk worth $3.71M as of Q2 2024.
  • Benjamin F. Edwards & Company bought 57 Novo Nordisk shares in Q2 2024, an estimated $7.55K.
  • Novo Nordisk made up 0.07% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #274 holding.
  • Benjamin F. Edwards & Company first reported a position in Novo Nordisk in Q1 2014 and has held it in 42 quarters since.
  • 1,863 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.